← Back to Search

Selective Serotonin Reuptake Inhibitor (SSRI)

A for Obsessive-Compulsive Disorder

Phase 4
Waitlist Available
Led By John H Greist, MD
Research Sponsored by Rogers Center for Research & Training, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Men and women aged 18 years, with OCD of at least 1 year's duration, meeting DSM-IV diagnostic criteria, and having a baseline Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of 18.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This study will test the hypotheses that: 1. 12 weeks of Luvox-CR plus web-based Cognitive-Behavioral Therapy (CBT) \[CT-STEPS\] will produce greater symptom relief of OCD than treatment with Luvox-CR alone; and, 2. subjects receiving 12 weeks of CT-STEPS added to Luvox-CR treatment after 12-weeks of Luvox-CR monotherapy will experience greater OCD symptom relief (from weeks 12-24) than those continuing Luvox-CR treatment and having access to CT-STEPS from week one. 3. subjects who begin CT-STEPS at week 12 will be more likely to complete it than those who begin CT-STEPS at baseline.

Eligible Conditions
  • Obsessive-Compulsive Disorder

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: AExperimental Treatment2 Interventions
Effectiveness of Luvox CR plus Web-based CBT for OCD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Behavioral Therapy
2003
Completed Phase 4
~1210

Find a Location

Who is running the clinical trial?

Rogers Center for Research & Training, Inc.Lead Sponsor
1 Previous Clinical Trials
20 Total Patients Enrolled
John H Greist, MDPrincipal InvestigatorThe Rogers Center for Research & Training, Inc.
1 Previous Clinical Trials
20 Total Patients Enrolled
~3 spots leftby Sep 2025